Lenalidomide Amarox

Lenalidomide, the active ingredient in Lenalidomide Amarox, is an immunomodulatory agent presented as a tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients. Lenalidomide Amarox is marketed in the European Union and complies with relevant regulatory standards.

GNH USA supplies Lenalidomide Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide Amarox is an immunomodulatory antineoplastic that acts on malignant plasma cells and related pathways.

Multiple myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. Myelodysplastic syndromes: reduces transfusion dependence and improves blood counts in patients with del(5q) cytogenetic abnormality. Mantle cell lymphoma: contributes to disease control when used in combination therapy.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue - Neutropenia - Thrombocytopenia - Diarrhea - Rash - Constipation

Serious or Rare Side Effects: - Venous thromboembolism - Severe neutropenia leading to infection - Secondary primary malignancies - Hepatic toxicity - Severe skin reactions such as Stevens‑Johnson syndrome - Life‑threatening infections

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks.

Pregnancy: Contraindicated; teratogenic (Category X). Blood monitoring: Regular CBC to detect neutropenia or thrombocytopenia. Thromboembolism risk: Assess for prophylactic anticoagulation in high‑risk patients. Renal function: Adjust use in severe renal impairment. Hypersensitivity: Discontinue if allergic reactions occur. Store at below 25°C: keep in original packaging, protect from moisture and light.

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase exposure. - Potent CYP3A4 inducers (e.g., rifampin) may reduce efficacy. - Anticoagulants (e.g., warfarin) can heighten bleeding risk. - Immunosuppressants (e.g., cyclosporine) may amplify toxicity. - Live vaccines: increased risk of infection.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., midazolam) may require dose adjustment. - NSAIDs: monitor for additive platelet effects. - Hormonal contraceptives: reduced effectiveness. - Antihypertensives: potential blood pressure changes. - P‑glycoprotein substrates: altered plasma levels.